HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Feinstein’s Cosmetics Safety Bill Launches With GOP Cosponsor

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Safety Act would preempt duplicative state-level requirements for ingredient use and manufacturer responsibilities, addressing what has become one of the foremost banes of industry in recent years, while increasing FDA’s authority over the sector and giving it new responsibilities with regard to ingredient safety review. Additional compliance requirements for industry could prove challenging, but the positive PR likely to result from the legislation could help soften the blow.

You may also be interested in...



Cosmetics Provisions Unlikely To Catch Ride On FDA User-Fee Bill

With the release of an atypically lean, clean FDA user-fee reauthorization draft bill, it’s doubtful that cosmetics regulatory reform language will get tacked onto the must-pass legislation. Stakeholders likely will refocus their efforts on standalone cosmetics legislation to modernize FDA’s oversight of the industry.

FDA: Ingredient Safety Decisions Under PCPSA Could Differ From CIR

Compared with the Cosmetic Ingredient Review, FDA could consider a wider selection of data in its ingredient safety evaluations under the Personal Care Products Safety Act, an FDA official says. Further, industry would have the burden of demonstrating reasonable certainty of no harm, a high bar to clear.

Sen. Alexander Questions FDA's Slow Response To WEN Complaints

In a letter to FDA leadership, Sen. Lamar Alexander, R-Tenn., asks the agency to explain its current regulatory authorities over cosmetics and limitations under current law, as well as how it handles adverse-event reports and takes action against non-compliant products. Alexander chairs the Senate HELP Committee and raised concerns at a recent hearing about FDA’s response to WEN.

Related Content

UsernamePublicRestriction

Register

RS019458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel